Roche’s Lucentis Backed by FDA Panel for Diabetic Blindness

Roche Holding AG’s Lucentis won the backing of U.S. regulatory advisers for expanded use to treat a leading cause of blindness associated with diabetes.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.